- SpiSparc first five patients have been enrolled and dosed into its ongoing clinical trial for children with autism.
- The double-blind, randomized and placebo-controlled trial uses SciSparc's proprietary SCI-210.
- SCI-210, a combination of CBD and CannAmide, which is designed to alleviate autism symptoms.
- A new wave of value and momentum stocks could be setting up for major moves—and Tim Melvin will name them live this Wednesday. Secure access here.
SciSparc Ltd. SPRC announced on Tuesday that the first five patients have been enrolled and dosed into its ongoing clinical trial in children suffering from autism spectrum disorder (ASD) at the Soroka Medical Center in Israel.
What Happened
The Israeli specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system enrolled the first patient in March to its clinical trial assessing the efficacy and safety of its cannabidiol (CBD)– based drug for the treatment of children with autism spectrum disorder.
The double-blind, randomized and placebo-controlled trial uses SciSparc’s proprietary SCI-210, a combination of CBD and CannAmide– the company’s Palmitoylethanolamide – which is designed to alleviate ASD symptoms. The trial was designed in consultation with the National Autism Research Center.
The company signed an agreement with Israel's manufacturer and distributor of cannabis-based products, Tikun Olam Cannbit Pharmaceuticals Ltd., to supply its CBD-rich oil from Cannbit strains to be used as part of SCI-210 treatment, last year.
Read Also: Cannabis & Children Autism: New Study Claims CBDA Can Help With Behavioral Issues In Kids With ASD
Why It Matters
"People of all genders, ethnicities and economic backgrounds can be diagnosed with ASD," Oz Adler, SciSparc's CEO said. "Although ASD can be a lifelong disorder, treatments and services can improve a person's symptoms and daily functioning. Consistent with our mission of improving people's lives, we are happy with the ongoing pace of enrollment in the SCI-210 trial and expect that this study will generate new scientific data so that others may be better helped in the future."
What's Next
The company plans to enroll 60 subjects between the ages of five and eighteen for twenty weeks, to assess how SCI-210 therapy compares to standard CBD monotherapy in managing symptoms of ASD.
SciSparc seeks to sell SCI-210 first in Israel and then in other countries, subject to obtaining the requisite regulatory approvals.
Now read:
SPRC Price Action
SciSparc’s shares traded 0.8333% higher at $0.4235 per share at the time of writing on Tuesday morning.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
